Literature DB >> 33661394

Are there sex differences among colorectal cancer patients in treatment and survival? A Swiss cohort study.

Manuela Limam1,2, Katarina Luise Matthes1,2, Giulia Pestoni1,2, Eleftheria Michalopoulou1, Leonhard Held1, Silvia Dehler1,2, Dimitri Korol2, Sabine Rohrmann3,4.   

Abstract

BACKGROUND: Colorectal cancer (CRC) is among the three most common incident cancers and causes of cancer death in Switzerland for both men and women. To promote aspects of gender medicine, we examined differences in treatment decision and survival by sex in CRC patients diagnosed 2000 and 2001 in the canton of Zurich, Switzerland.
METHODS: Characteristics assessed of 1076 CRC patients were sex, tumor subsite, age at diagnosis, tumor stage, primary treatment option and comorbidity rated by the Charlson Comorbidity Index (CCI). Missing data for stage and comorbidities were completed using multivariate imputation by chained equations. We estimated the probability of receiving surgery versus another primary treatment using multivariable binomial logistic regression models. Univariable and multivariable Cox proportional hazards regression models were used for survival analysis.
RESULTS: Females were older at diagnosis and had less comorbidities than men. There was no difference with respect to treatment decisions between men and women. The probability of receiving a primary treatment other than surgery was nearly twice as high in patients with the highest comorbidity index, CCI 2+, compared with patients without comorbidities. This effect was significantly stronger in women than in men (p-interaction = 0.010). Survival decreased with higher CCI, tumor stage and age in all CRC patients. Sex had no impact on survival.
CONCLUSION: The probability of receiving any primary treatment and survival were independent of sex. However, female CRC patients with the highest CCI appeared more likely to receive other therapy than surgery compared to their male counterparts.

Entities:  

Keywords:  Colorectal cancer; Comorbidity; Sex differences; Survival; Treatment

Mesh:

Year:  2021        PMID: 33661394     DOI: 10.1007/s00432-021-03557-y

Source DB:  PubMed          Journal:  J Cancer Res Clin Oncol        ISSN: 0171-5216            Impact factor:   4.553


  43 in total

1.  Improved survival with preoperative radiotherapy in resectable rectal cancer.

Authors:  B Cedermark; M Dahlberg; B Glimelius; L Påhlman; L E Rutqvist; N Wilking
Journal:  N Engl J Med       Date:  1997-04-03       Impact factor: 91.245

2.  Preoperative radiotherapy as adjuvant treatment in rectal cancer. Final results of a randomized study of the European Organization for Research and Treatment of Cancer (EORTC).

Authors:  A Gérard; M Buyse; B Nordlinger; J Loygue; F Pène; P Kempf; J F Bosset; M Gignoux; J P Arnaud; C Desaive
Journal:  Ann Surg       Date:  1988-11       Impact factor: 12.969

3.  Multimorbidity and survival in older persons with colorectal cancer.

Authors:  Cary P Gross; Zhenchao Guo; Gail J McAvay; Heather G Allore; Mary Young; Mary E Tinetti
Journal:  J Am Geriatr Soc       Date:  2006-12       Impact factor: 5.562

4.  Patterns of care for adjuvant therapy in a random population-based sample of patients diagnosed with colorectal cancer.

Authors:  Deirdre P Cronin; Linda C Harlan; Arnold L Potosky; Limin X Clegg; Jennifer L Stevens; Margaret M Mooney
Journal:  Am J Gastroenterol       Date:  2006-10       Impact factor: 10.864

5.  Comparison of 17,641 patients with right- and left-sided colon cancer: differences in epidemiology, perioperative course, histology, and survival.

Authors:  Frank Benedix; Rainer Kube; Frank Meyer; Uwe Schmidt; Ingo Gastinger; Hans Lippert
Journal:  Dis Colon Rectum       Date:  2010-01       Impact factor: 4.585

6.  Charlson Index comorbidity adjustment for ischemic stroke outcome studies.

Authors:  Larry B Goldstein; Gregory P Samsa; David B Matchar; Ronnie D Horner
Journal:  Stroke       Date:  2004-07-01       Impact factor: 7.914

7.  The impact of chronic illnesses on the use and effectiveness of adjuvant chemotherapy for colon cancer.

Authors:  Cary P Gross; Gail J McAvay; Zhenchao Guo; Mary E Tinetti
Journal:  Cancer       Date:  2007-06-15       Impact factor: 6.860

Review 8.  Impact of comorbidity and frailty on prognosis in colorectal cancer patients: A systematic review and meta-analysis.

Authors:  Daniel Boakye; Bettina Rillmann; Viola Walter; Lina Jansen; Michael Hoffmeister; Hermann Brenner
Journal:  Cancer Treat Rev       Date:  2018-02-10       Impact factor: 12.111

9.  Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012.

Authors:  Jacques Ferlay; Isabelle Soerjomataram; Rajesh Dikshit; Sultan Eser; Colin Mathers; Marise Rebelo; Donald Maxwell Parkin; David Forman; Freddie Bray
Journal:  Int J Cancer       Date:  2014-10-09       Impact factor: 7.396

10.  Gender differences in colorectal cancer: implications for age at initiation of screening.

Authors:  H Brenner; M Hoffmeister; V Arndt; U Haug
Journal:  Br J Cancer       Date:  2007-02-20       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.